Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TNF | P01375 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7635249 | 0.81 | P2RX7 (0.33) | ACHECYP3A4RAPGEF4P2RX7HDAC1 | |
| SCHEMBL31713181 | 0.79 | TNF (0.38) | TNFRIPK1HTR2AHTR2CHTR2B | |
| SCHEMBL21598620 | 0.79 | TNF (0.38) | TNFRIPK1HTR2AHTR2CHTR2B | |
| SCHEMBL13905953 | 0.77 | ACHE (0.38) | ACHECYP3A4TNFRIPK1RAPGEF4 | |
| SCHEMBL11261447 | 0.77 | ACHE (0.38) | ACHEHDAC1HDAC6 | |
| SCHEMBL2578269 | 0.77 | ACHE (0.38) | ACHECYP3A4TNFRIPK1RAPGEF4 | |
| SCHEMBL10262185 | 0.75 | ACHE (0.36) | ACHECYP3A4TNFRIPK1RAPGEF4 | |
| SCHEMBL30614630 | 0.75 | ACHE (0.36) | ACHEHDAC1HDAC6 | |
| SCHEMBL15703816 | 0.75 | ACHE (0.36) | ACHEHDAC1HDAC6 | |
| SCHEMBL19830027 | 0.75 | CYP3A4 (0.36) | CYP3A4HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2680850-B1 | ALKYNE SUBSTITUTED QUINAZOLINE COMPOUND AND METHODS OF USE | NEWGEN THERAPEUTICS INC (US) | 2018-05-23 | — | — | EP | disclosed |
| US-9187459-B2 | Quinazoline-7-ether compounds and methods of use | NEWGEN THERAPEUTICS, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-9187459-B2 | Quinazoline-7-ether compounds and methods of use | NEWGEN THERAPEUTICS, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-8987284-B2 | Phosphorus containing quinazoline compounds and methods of use | NEWGEN THERAPEUTICS, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987284-B2 | Phosphorus containing quinazoline compounds and methods of use | NEWGEN THERAPEUTICS, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20140221406-A1 | QUINAZOLINE-7-ETHER COMPOUNDS AND METHODS OF USE | NEWGEN THERAPEUTICS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221406-A1 | QUINAZOLINE-7-ETHER COMPOUNDS AND METHODS OF USE | NEWGEN THERAPEUTICS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| WO-2012158979-A1 | QUINAZOLINE-7-ETHER COMPOUNDS AND METHODS OF USE | NEWGEN THERAPEUTICS, INC. (US) | 2012-11-22 | — | — | WO | disclosed |
| US-20120196833-A1 | PHOSPHORUS CONTAINING QUINAZOLINE COMPOUNDS AND METHODS OF USE | NEWGEN THERAPEUTICS, INC. | 2012-08-02 | — | — | US | disclosed |
| US-20120196833-A1 | PHOSPHORUS CONTAINING QUINAZOLINE COMPOUNDS AND METHODS OF USE | NEWGEN THERAPEUTICS, INC. | 2012-08-02 | — | — | US | disclosed |
| WO-2011002523-A1 | PHOSPHORUS CONTAINING QUINAZOLINE COMPOUNDS AND METHODS OF USE | KANIONUSA INC. (US) | 2011-01-06 | — | — | WO | disclosed |
| CN-101687812-A | The 2-imidazolinium compounds that trace amine associated receptors (TAAR) is had good affinity | HOFFMANN LA ROCHE | 2010-03-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221406-A1 | QUINAZOLINE-7-ETHER COMPOUNDS AND METHODS OF USE | ABL1, ERBB4, ERBB2 | ACHE 4334/4885CYP3A4 1401/4885TNF 4326/4885 |
| US-20120196833-A1 | PHOSPHORUS CONTAINING QUINAZOLINE COMPOUNDS AND METHODS OF USE | PPIP5K2, PIK3CA, PHKA1 | ACHE 2756/4885CYP3A4 3767/4885TNF 3617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.